A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products

Change in Visual Acuity from Baseline Over Time, per Approved Retinal Indication and Product

Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.

Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)

Percentage of Eyes on Each Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other) Over Time, per Approved Retinal Indication and Product

Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)

Number of Treatments Over Time, per Approved Retinal Indication and Product

Time frame: At 3, 6, and 12 months, and annually thereafter (up to 5 years)

Cumulative Time Spent on Each Treatment per Eye, Overall and per Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other), per Approved Retinal Indication and Product

Time frame: From Baseline until end of study (up to 5 years)

Percentage of Eyes with Treatment Switch by Reason for Switch Over Time, per Approved Retinal Indication and Product

Time frame: At 3, 6, and 12 months, and annually thereafter (up to 5 years)

Percentage of Eyes with Treatment Regimen Switch (Fixed, Treat-and-Extend, As Needed, or Other) by Reason for Switch Over Time, per Approved Retinal Indication and Product

Time frame: At 3, 6, and 12 months, and annually thereafter (up to 5 years)

Total Number of Visits per Year, per Approved Retinal Indication and Product

Time frame: Annually (up to 5 years)

Number of Visits With or Without Treatment per Year, per Approved Retinal Indication and Product

Time frame: Annually (up to 5 years)

Time Interval Between Treatments per Year, per Approved Retinal Indication and Product

Time frame: Annually (up to 5 years)

Number of Eyes Treated with Ocular Concomitant and Subsequent Medications by Type and Frequency During the Study, per Approved Retinal Indication and Product

Time frame: From Baseline until end of study (up to 5 years)

Change in Visual Acuity from Baseline Over Time, According to Treatment Regimen (Fixed, Treat-and-Extend, As Needed, or Other), per Approved Retinal Indication and Product

Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.

Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)

Change in Visual Acuity from Baseline Over Time, According to Number of Treatments, per Approved Retinal Indication and Product

Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.

Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)

Change in Visual Acuity from Baseline Over Time, According to Total Number of Visits, per Approved Retinal Indication and Product

Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.

Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)

Change in Visual Acuity from Baseline Over Time, According to Treatment Schedule, per Approved Retinal Indication and Product

Visual acuity will be collected as measured per local practice and then will be converted to the approximate ETDRS letter score.

Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)

Change in Central Subfield Thickness (CST) from Baseline Over Time, per Approved Retinal Indication and Product

Time frame: Baseline, 3, 6, and 12 months, and annually thereafter (up to 5 years)

Number of Participants with at Least One Ocular Adverse Event, by Severity and Seriousness, per Approved Retinal Indication and Product

Severity and seriousness will be independently assessed for each adverse event (AE). The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe); the event itself may be of relatively minor medical significance.

Time frame: From Baseline until end of study (up to 5 years)

Number of Participants with at Least One Non-Ocular Adverse Event, by Severity and Seriousness, per Approved Retinal Indication and Product

Severity and seriousness will be independently assessed for each adverse event (AE). The terms "severe" and "serious" are not synonymous. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe); the event itself may be of relatively minor medical significance.

Time frame: From Baseline until end of study (up to 5 years)